steve-debenport-1

steve-debenport-1 / iStockphoto.com

17 May 2018Americas

Illumina and Sequenom take on Ariosa in DNA patent infringement case

Illumina and Sequenom have filed a patent infringement case against Ariosa Diagnostics for a patent covering DNA testing in pregnant women.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Court invalidates Illumina patents in Ariosa row

2 January 2019 Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.

Sequenom and Illumina prevail in UK confidentiality dispute

24 January 2019 The England and Wales High Court has ruled in favour of Sequenom and Illumina, after the companies asked the court to rule that they were entitled to receive confidential information in legal proceedings against three competitors without additional restriction.

More on this story

Court invalidates Illumina patents in Ariosa row

2 January 2019 Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.

Sequenom and Illumina prevail in UK confidentiality dispute

24 January 2019 The England and Wales High Court has ruled in favour of Sequenom and Illumina, after the companies asked the court to rule that they were entitled to receive confidential information in legal proceedings against three competitors without additional restriction.

More on this story

Court invalidates Illumina patents in Ariosa row

2 January 2019 Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.

Sequenom and Illumina prevail in UK confidentiality dispute

24 January 2019 The England and Wales High Court has ruled in favour of Sequenom and Illumina, after the companies asked the court to rule that they were entitled to receive confidential information in legal proceedings against three competitors without additional restriction.

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic